Targeting a specific enzyme to improve treatment for neuroblastoma
Targeting EP300, a selective dependency in neuroblastoma
This study is looking at new treatments for kids with high-risk neuroblastoma, a tough type of cancer, by using a special molecule to target a key part of the cancer's growth while keeping healthy cells safe, and it aims to find the best ways to combine these treatments for better results.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | St. Jude Children's Research Hospital NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-10906026 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for children with high-risk neuroblastoma, a type of cancer that currently has poor survival rates despite aggressive treatment. The approach involves targeting the enzyme EP300, which is crucial for the cancer's growth, while minimizing harm to normal cells. By using a novel molecule called JQAD1, the researchers aim to selectively degrade EP300, leading to tumor cell death with fewer side effects. The study will explore the most effective combinations of treatments to enhance the efficacy of this targeted approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with high-risk neuroblastoma who may benefit from new therapeutic strategies.
Not a fit: Patients with low-risk neuroblastoma or those who do not have neuroblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for children suffering from neuroblastoma.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, indicating a potential for success with this novel approach.
Where this research is happening
Memphis, United States
- St. Jude Children's Research Hospital — Memphis, United States (Active)
Researchers
- Principal investigator: Durbin, Adam David — St. Jude Children's Research Hospital
- Study coordinator: Durbin, Adam David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.